comparemela.com

Latest Breaking News On - Chemomab therapeutics ltd - Page 3 : comparemela.com

Chemomab Awarded New European Patent for CM-101, Its

Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories..

Wadi morBarbara lindheimEuropean patent office grants new coveringEuropean patent officeStrategic communicationsChemomab therapeutics ltdMultiple liverPrimary sclerosing cholangitisFurther extends protections affordedUse patentsThat have issuedRelated territoriesChief executive officerChief scientific officerPatent applicationOrphan drug

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis Further Extends Protections Afforded by.

Wadi morBarbara lindheimEuropean patent office grants new coveringEuropean patent officeStrategic communicationsChemomab therapeutics ltdMultiple liverPrimary sclerosing cholangitisFurther extends protections affordedUse patentsThat have issuedRelated territoriesChief executive officerChief scientific officerPatent applicationOrphan drug

Chemomab Therapeutics (NASDAQ:CMMB) Issues Earnings Results

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14, Zacks reports. During the same period in the previous year, the firm earned ($0.72) earnings per share. Chemomab Therapeutics Stock Performance Shares of CMMB stock […]

Roth mkmChemomab therapeutics ltdRenaissance technologiesBoothbay fund managementChemomab therapeutics company profileCitadel advisorsEnvestnet asset management incChemomab therapeuticsGet free reportSigma investmentsFund managementEnvestnet asset managementTherapeutics ltdChemomab therapeutics dailyNasdaq cmmb

Chemomab Therapeutics (NASDAQ:CMMB) Announces Earnings Results

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) issued its earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14, Zacks reports. During the same period in the previous year, the company posted ($0.72) earnings per share. Chemomab Therapeutics Stock Down 3.1 % Shares of NASDAQ:CMMB […]

Roth mkmRenaissance technologiesCitadel advisorsBoothbay fund managementChemomab therapeutics company profileEnvestnet asset management incChemomab therapeutics ltdChemomab therapeuticsGet free reportTherapeutics stock downAsset managementFund managementTwo sigma investmentsTherapeutics ltdChemomab therapeutics daily

Chemomab Therapeutics (CMMB) Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics (CMMB) Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Wadi morChemomab therapeutics ltdEuropean unionChemomab therapeuticsPatent officesThat recognize additionalChief executive officerChief scientific officerOrphan drug

vimarsana © 2020. All Rights Reserved.